Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ: EWTX ) with a Neutral and raises the price target from $32 to $36.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.